处理计划系统之间的数据传输对剂量计量参数的影响
Guenda Meffe1, Claudio Votta1, Gabriele Turco1
1Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
概括
在放射治疗治疗计划系统 (TPS) 之间转移医学数字成像和通信 (DICOM) 数据集导致计划目标体积和风险参数器官的显著变化. 这些变化需要在治疗期间进行临床考虑.
科学领域:
- 放射治疗 物理 物理
- 医疗成像医学成像
- 辐射瘤学 辐射瘤学
背景情况:
- 放射治疗需要在治疗计划系统 (TPS) 之间传输DICOM数据集,用于各种临床应用.
- 评估这些数据传输对治疗计划的影响对于患者安全和治疗疗效至关重要.
研究的目的:
- 评估不同TPS之间的DICOM数据集转移对剂量计参数和解剖结构的影响.
- 量化数据传输后规划目标体积 (PTV) 和风险器官 (OAR) 的变化.
主要方法:
- 包括25名本地晚期胰腺癌患者,接受0.35TMR-Linac治疗.
- 剂量分配得到了优化,计划从MRidian-TPS转移到Eclipse-TPS.
- 比较的重点是PTV/OAR的数量,剂量覆盖范围和临床约束的遵守.
主要成果:
- 观察到PTV体积的中位数变化为10.8%,平均PTV覆盖率差异为-1.4%.
- 中位数OAR的体积变化范围从7.0% (胃) 到16.0% (十二指肠).
- 对十二指肠 (41.0%),胃 (52.7%) 和小肠 (49.8%) 发现了显著的剂量限制变化.
结论:
- 在TPS之间数据集的转移会导致解剖学和剂量测量数据的变化.
- 这些变化需要在放射治疗重复治疗或计划总结期间进行仔细的临床考虑.
- 需要对TPS使用的DICOM结构算法进行进一步的调查,以了解这些差异的根本原因.
关键词:
迪科姆数据集是DICOM的数据集.剂量测量参数 剂量计参数在MRgRTRT中,您可以使用MRgRT.在OARAROAROAROAROAROAROAROAROAROAROAROAROAROAROAROAROAROAROAROAR辐射疗法 辐射疗法在TPS中使用TPS.更多相关视频
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.3K
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
2.8K
相关概念视频
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
363
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
363
01:24Dosage Regimen: Individualization
398
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
398
01:21Dose Size and Dosing Frequency: Determination Methods
804
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
804
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
394
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
394
01:29Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429